Document is current
Any future updates will be listed below
-
Authors
Perez, David H. https://orcid.org/0000-0003-0684-6325
Antfolk, Daniel https://orcid.org/0000-0001-9163-3740
Chang, Shiun
Bustos, Xiomar E. https://orcid.org/0009-0004-2840-758X
Medina, Elliot https://orcid.org/0000-0002-3119-0981
Ramadan, Ahmed A.
Gonzalez-Perez, David https://orcid.org/0000-0001-9613-4705
Abate-Daga, Daniel
Rodriguez, Paulo C. https://orcid.org/0000-0001-7480-6566
Luca, Vincent C. https://orcid.org/0000-0001-9427-5520
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM133482, R35GM133482)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA076292)
Rita Allen Foundation
Sigrid Juselius Foundation
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 20 August 2025
First Online: 24 September 2025
Competing interests
: V.C.L. is a consultant on unrelated projects for Cellestia Biotech, Remunix and Curie.Bio. V.C.L. and D.H.P. have filed provisional patents (63/548,615 and 63/663,744) based on the described technology. The other authors declare no competing interests.
